“This acquisition carries two major strategic implications for MEDiC,” said Kyuho Han, CEO of MEDiC. “In the near term, it allows us to relaunch a clinical-stage asset in an SLS biomarker-defined patient cohort, creating a Phase II–ready program. In the long-term, its success will serve as a key validation of our platform. By identifying synthetic-lethal biomarkers that enhance the clinical success of cancer therapies, we can unlock a new wave of precision medicines – developed faster, at lower cost, and, most importantly, for the benefit of cancer patients, which remains our highest priority.”